Stefan Anker

Professor of Cardiology

Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany

  • OrcidID

Biography

Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.

Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.

Prof Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle.

Read more

Media

Stefan Anker, Andrew JS Coats, Shelley Zieroth, et al

Stefan Anker, Andrew JS Coats, Shelley Zieroth, et al

Andrew JS Coats, Stefan Anker,

Andrew JS Coats, Shelley Zieroth, Javed Butler, et al

John JV McMurray, Stefan Anker, , et al

Aktualisierungen der europäischen Leitlinien zur Herzinsuffizienz: Eine Peer-to-Peer-Diskussion über SGLT-2-Hemmer

Gerd Hasenfuß, Michael Böhm, Stefan Anker, et al

ESC 2021 Discussion: The EMPEROR-Preserved Trial

Stefan Anker, Harriette Van Spall,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Shelley Zieroth, Stefan Anker,

Martin R Cowie, Shelley Zieroth, Nikolaus Marx, et al

Andrew JS Coats, Piotr Ponikowski, Stefan Anker, et al

Past, Present and Future: SGLT2 Inhibitors

Andrew JS Coats, Stefan Anker, John JV McMurray, et al

Past, Present and Future: SGLT2 Inhibitors for Cardiovascular Outcomes - Where are we now?

Andrew JS Coats, Stefan Anker, John JV McMurray, et al

Past, Present and Future: SGLT2 Inhibitors

Andrew JS Coats, Stefan Anker, John JV McMurray, et al

Andrew JS Coats, Faiez Zannad, Stefan Anker, et al

Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitu

Stefan Anker, Andrew JS Coats,

ESC 2018: Use of SGLT2 inhibitors in clinical practice to reduce CV mortality in patients with type 2 diabetes

Javed Butler, Stefan Anker,

ESC 2017: Baroreflex Activation Therapy for HF

Stefan Anker,